# Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

> **NCT05554003** · PHASE2 · RECRUITING · sponsor: **European Institute of Oncology** · enrollment: 46 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Frailty
- Chemotherapy Effect

## Interventions

- **DRUG:** Temozolomide capsule

## Key facts

- **NCT ID:** NCT05554003
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-14
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05554003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05554003, "Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05554003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*